Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 6,349 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 6,349 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $28.99, for a total transaction of $184,057.51. Following the completion of the transaction, the insider owned 50,437 shares of the company’s stock, valued at approximately $1,462,168.63. This represents a 11.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

David Malcom Rodman also recently made the following trade(s):

• On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total transaction of $385,669.20.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total transaction of $65,585.91.
• On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total transaction of $13,353.60.
• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total value of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total value of $252,469.75.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.32, for a total value of $205,167.36.
• On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $33.27, for a total value of $72,195.90.
• On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.87, for a total value of $2,512,227.19.
• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total value of $6,748,879.30.

Mineralys Therapeutics Stock Down 0.9%

Mineralys Therapeutics stock traded down $0.26 during mid-day trading on Friday, hitting $27.60. 1,068,870 shares of the company were exchanged, compared to its average volume of 1,077,399. The company has a market capitalization of $2.18 billion, a PE ratio of -9.36 and a beta of 0.51. The business has a fifty day moving average of $33.89 and a 200 day moving average of $33.41. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.14. Research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Analysts Set New Price Targets

MLYS has been the topic of several research analyst reports. Stifel Nicolaus upped their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. HC Wainwright boosted their target price on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company lifted their price objective on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.43.

Institutional Trading of Mineralys Therapeutics

Hedge funds have recently modified their holdings of the stock. State Street Corp raised its position in Mineralys Therapeutics by 144.4% in the 4th quarter. State Street Corp now owns 3,184,999 shares of the company’s stock worth $115,584,000 after purchasing an additional 1,881,976 shares during the last quarter. Farallon Capital Management LLC bought a new position in Mineralys Therapeutics in the 3rd quarter valued at $63,442,000. Holocene Advisors LP bought a new position in Mineralys Therapeutics in the 3rd quarter valued at $45,708,000. RA Capital Management L.P. increased its stake in shares of Mineralys Therapeutics by 19.1% in the 3rd quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock valued at $277,717,000 after buying an additional 1,176,470 shares during the period. Finally, Polar Capital Holdings Plc bought a new stake in shares of Mineralys Therapeutics during the third quarter worth $40,149,000. 84.46% of the stock is owned by institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.